U.S., Aug. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07122700) titled 'Evaluation of Non-Invasive Tests for Metabolic Liver Disease' on Aug. 07.
Brief Summary: The Non-Invasive Biomarkers for Metabolic Liver Disease (NIMBLE) study is a comprehensive, multi-year collaborative effort to standardize, validate and advance the regulatory qualification of blood- and imaging-based biomarkers to diagnose and stage Metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH). MASH is characterized by liver inflammation accompanied by simultaneous fat accumulation in the liver.
Study Start Date: May 13
Study Type: OBSERVATIONAL
Condition:
Metabolic Associat...